CannTrust, InMed Gain Approval To List On The TSX

CannTrust Holdings Inc. (TRST), a licensed medical cannabis producer, announced today that is has been granted approval to commence trading on the Toronto Stock Exchange (TSX), effective March 5, 2018. Shares of the company will continue to trade under the symbol TRST.

Recently the company was awarded a Health Canada Sales License for the 250,000 square foot Phase 1 expansion of its 46 acre Niagara Region cannabis production facility.

As part of its listing on the TSX, the company will voluntarily delist itself from the Canadian Securities Exchange (CSE), effective by the close of trading on March 2, 2018.

“Graduating to the TSX reflects the amazing progress we have made since listing on the CSE in August last year and represents yet another important milestone for CannTrust as we continue our successful journey as one of Canada’s leading cannabis companies” said Eric Paul, Chief Executive Officer of CannTrust, in a statement.

InMed Gains Conditional Approval

In related news, InMed Pharmaceuticals Inc. (IN), a pre-clinical biopharmaceutical company specializing in cannabinoid-based medicines, announced today that it had been granted conditional approval to list its shares on the TSX.

“Graduating to the TSX is a significant accomplishment for InMed,” said Eric A. Adams, CEO and President of InMed, in a statement. “This milestone furthers our corporate goal of securing a leadership position in this high-growth sector. InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world’s senior stock exchanges.”

Final approval of the listing remains dependent on the company fulfilling certain customary listing conditions by May 29, 2018. This would include a divestment in any assets held in the United States cannabis industry; where cannabis is still federally illegal. One company, Aphria Inc., has already begun to divest from the US market, and more are sure to follow as Canada prepares launch recreational cannabis sales later this year.

Like CannTrust, InMed will voluntarily delist its from the CSE once granted final approval. Shareholders will not have to change their stock certificates or take any further action.

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 2 days

Happy Friday! Marijuana Money July 23, 2021

@GreenMarketRpt – 4 days

RT : I spoke with to discuss cannabis stock options worth consideration, and why U.S. MSOs pique his interest…

Back to Top